These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 22258929)

  • 61. A systematic review of SARS-CoV-2 vaccine candidates.
    Dong Y; Dai T; Wei Y; Zhang L; Zheng M; Zhou F
    Signal Transduct Target Ther; 2020 Oct; 5(1):237. PubMed ID: 33051445
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Phospholipidation of TLR7/8-active imidazoquinolines using a tandem phosphoramidite method.
    Bazin HG; Bess LS; Livesay MT; Mwakwari SC; Johnson DA
    Tetrahedron Lett; 2016 May; 57(19):2063-2066. PubMed ID: 32863446
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A Single and Multiple Ascending Dose Study of Toll-Like Receptor 7 Agonist (RO7020531) in Chinese Healthy Volunteers.
    Luk A; Jiang Q; Glavini K; Triyatni M; Zhao N; Racek T; Zhu Y; Grippo JF
    Clin Transl Sci; 2020 Sep; 13(5):985-993. PubMed ID: 32268000
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Optimization of 8-oxoadenines with toll-like-receptor 7 and 8 activity.
    Bazin HG; Bess LS; Livesay MT; Li Y; Cybulski V; Miller SM; Johnson DA; Evans JT
    Bioorg Med Chem Lett; 2020 Mar; 30(6):126984. PubMed ID: 32001135
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Targeting Cellular and Tissue HIV Reservoirs With Toll-Like Receptor Agonists.
    Macedo AB; Novis CL; Bosque A
    Front Immunol; 2019; 10():2450. PubMed ID: 31681325
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Critical Role of B Cells in Toll-Like Receptor 7-Mediated Protection against Listeria monocytogenes Infection.
    Kayraklioglu N; Horuluoglu B; Elango M; Klinman DM
    Infect Immun; 2019 Dec; 87(12):. PubMed ID: 31591164
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Synthetic Toll-like Receptors 7 and 8 Agonists: Structure-Activity Relationship in the Oxoadenine Series.
    Evans JT; Bess LS; Mwakwari SC; Livesay MT; Li Y; Cybulski V; Johnson DA; Bazin HG
    ACS Omega; 2019 Sep; 4(13):15665-15677. PubMed ID: 31572869
    [TBL] [Abstract][Full Text] [Related]  

  • 68. 5-Oxo-1-[(2,3,6,7-tetramethoxy-9-phenanthrenyl)methyl]-L-proline Inhibits Hepatitis C Virus Entry.
    Nguyen LP; Park C; Luong TTD; Park EM; Choi DH; Han KM; Mai HN; Nguyen HC; Lim YS; Hwang SB
    Sci Rep; 2019 May; 9(1):7288. PubMed ID: 31086268
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Identification of a small molecule that primes the type I interferon response to cytosolic DNA.
    Khiar S; Lucas-Hourani M; Nisole S; Smith N; Helynck O; Bourgine M; Ruffié C; Herbeuval JP; Munier-Lehmann H; Tangy F; Vidalain PO
    Sci Rep; 2017 May; 7(1):2561. PubMed ID: 28566766
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Evaluation of novel synthetic TLR7/8 agonists as vaccine adjuvants.
    Smith AJ; Li Y; Bazin HG; St-Jean JR; Larocque D; Evans JT; Baldridge JR
    Vaccine; 2016 Aug; 34(36):4304-12. PubMed ID: 27402566
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Novel adjuvant formulations for delivery of anti-tuberculosis vaccine candidates.
    Agger EM
    Adv Drug Deliv Rev; 2016 Jul; 102():73-82. PubMed ID: 26596558
    [TBL] [Abstract][Full Text] [Related]  

  • 72. TLR activation and ionizing radiation induce strong immune responses against multiple tumor entities.
    Schölch S; Rauber C; Weitz J; Koch M; Huber PE
    Oncoimmunology; 2015 Nov; 4(11):e1042201. PubMed ID: 26451314
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Radiotherapy combined with TLR7/8 activation induces strong immune responses against gastrointestinal tumors.
    Schölch S; Rauber C; Tietz A; Rahbari NN; Bork U; Schmidt T; Kahlert C; Haberkorn U; Tomai MA; Lipson KE; Carretero R; Weitz J; Koch M; Huber PE
    Oncotarget; 2015 Mar; 6(7):4663-76. PubMed ID: 25609199
    [TBL] [Abstract][Full Text] [Related]  

  • 74. New pharmacological strategies to fight enveloped viruses.
    Wisskirchen K; Lucifora J; Michler T; Protzer U
    Trends Pharmacol Sci; 2014 Sep; 35(9):470-8. PubMed ID: 25108320
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine.
    Iwata-Yoshikawa N; Uda A; Suzuki T; Tsunetsugu-Yokota Y; Sato Y; Morikawa S; Tashiro M; Sata T; Hasegawa H; Nagata N
    J Virol; 2014 Aug; 88(15):8597-614. PubMed ID: 24850731
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Toll-like receptor 3 genetic variants and susceptibility to hepatocellular carcinoma and HBV-related hepatocellular carcinoma.
    Li G; Zheng Z
    Tumour Biol; 2013 Jun; 34(3):1589-94. PubMed ID: 23404408
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Association of Toll-like receptor 3 polymorphisms with chronic hepatitis B and hepatitis B-related acute-on-chronic liver failure.
    Rong Y; Song H; You S; Zhu B; Zang H; Zhao Y; Li Y; Wan Z; Liu H; Zhang A; Xiao L; Xin S
    Inflammation; 2013 Apr; 36(2):413-8. PubMed ID: 23076446
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Regulators of innate immunity as novel targets for panviral therapeutics.
    Es-Saad S; Tremblay N; Baril M; Lamarre D
    Curr Opin Virol; 2012 Oct; 2(5):622-8. PubMed ID: 23017246
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Antiviral applications of Toll-like receptor agonists.
    Horscroft NJ; Pryde DC; Bright H
    J Antimicrob Chemother; 2012 Apr; 67(4):789-801. PubMed ID: 22258929
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The pharmacology of endosomal TLR agonists in viral disease.
    Averett DR; Fletcher SP; Li W; Webber SE; Appleman JR
    Biochem Soc Trans; 2007 Dec; 35(Pt 6):1468-72. PubMed ID: 18031247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.